According to the agreement http://nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com/attachments/EBO/384370/361287.pdf, EBOS will buy the Australian and New Zealand units LifeHealthcare and 51% of its Asian unit, Transmedic, with funds advised by Pacific Equity partners and other minority owners.
“The acquisition … represents an important step in EBOS’s medical devices strategy, providing further exposure to this high-growth segment as well as entry into Southeast Asia,” said John Colletti, CEO of EBOS, in a press release.
The New Zealand company said the deal is expected to increase earnings per share from EBOS by double digits in 2022 on a pro forma basis.
LifeHealthcare, one of the largest independent distributors of medical devices and in-house allograft equipment in Australia, New Zealand and Southeast Asia, was acquired by Pacific Equity Partners in 2018.
EBOS said it will take on a retail offer to raise up to A$100 million, a stock offering to raise A$642 million and a A$540 million loan to fund the deal.
The company also said that its net income after tax (NPAT) increased 14% in the four months to October and that it plans to declare an annual dividend representing 60% to 80% of NPAT.
($1 = 3 1,3935 Australian dollars) (Reportage by Tejaswi Marthi Bengaluru; Editing by Shonak Dasgupta and Ramakrishnan M.)
“Organizer. Social media geek. General communicator. Bacon scholar. Proud pop culture trailblazer.”